Clinical Trials
11 trialsNCT04919382 2026-04-08
Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
Big Ten Cancer Research Consortium
Phase 2 Recruiting
NCT03728361 2025-12-18
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT00080938 2023-06-29
Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00740636 2016-08-01
Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02133677 2014-05-08
A Phase II Multi-center Pilot Study of Concurrent Temozolomide and Whole Brain Irradiation in Lung Cancer and Breast Cancer Patients With Brain Metastases
Far Eastern Memorial Hospital
Phase 2 Unknown
NCT00005037 2014-05-06
Temozolomide in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer
Fox Chase Cancer Center
Phase 2 Completed
NCT00006877 2014-01-08
Temozolomide in Treating Patients With Metastatic Non-small Cell Lung Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00385398 2013-09-02
QOL-Stereotactic RadioSurgery, Temozolomide + Erlotinib-Rx of 1-3 Brain Metastases in NSCLC
Rutgers, The State University of New Jersey
Phase 2 Withdrawn
NCT00022711 2013-07-11
Temozolomide in Treating Patients With Relapsed or Progressive Small Cell Lung Cancer
Fox Chase Cancer Center
Phase 2 Completed
NCT00003062 2012-07-02
Temozolomide in Patients With Progressive or Recurrent Non-small Cell Lung Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00238251 2012-06-05
Radiation Therapy Combined With Either Gefitinib or Temozolomide in Pats With NSCLC and Brain Metastases
Swiss Cancer Institute
Phase 2 Completed